Geneos Therapeutics Initiates IMPACT31 Phase 2 Randomized Clinical Trial Evaluating Neoantigen-Targeted Personalized DNA Immunotherapy for Cancer
The study evaluates patients with liver cancer at high risk of recurrence following surgical resection Julie Rosenberg, MD, appointed to leadership team as Chief Medical Officer PHILADELPHIA, Oct. 21, 2026 /PRNewswire/ -- Geneos Therapeutics, a clinical stage biotherapeutics company focused on the development of neoantigen-based personalized immunotherapy for cancer...
Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Becomes the 7th International Registrational Clinical Trial for Ivonescimab Clinical Trial Site Activations in the United States Expected to Begin Q4 2026 HONG KONG, Oct. 21, 2026 /PRNewswire/ -- Akeso, Inc. (HKEX: 9926.HK) today announced that Summit Therapeutics Inc. (NASDAQ: SMMT), its global partner for ivonescimab, has entered into a clinical trial collaboration with the ECOG-ACRIN...
Axtria Wins 2026 Minsky Award for Excellence in AI for the Third Consecutive Year
AI-powered Next Best Action solution generated more than $180 million in incremental revenue for a brand for a global pharmaceutical leader BERKELEY HEIGHTS, N.J., Oct. 21, 2026 /PRNewswire/ -- Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, has won the 2026 Minsky Award for...
China SXT Pharmaceuticals Inc Announces Termination of Additional Purchase Right
TAIZHOU, China, Oct. 21, 2026 /PRNewswire/ -- China SXT Pharmaceuticals Inc. (NASDAQ: SXTC) (the "Company"), today announced that it has entered into a termination letter agreement with the purchasers in its registered direct offering announced on October 8, 2026 (the "Offering"). Under the termination letter agreement, the Company and the purchasers have terminated in full the additional purchase...
Manulife and UpLink announce winners of the ‘Shaping Canada’s Longevity Advantage’ Challenge
Ten innovators selected for solutions that help Canadians live longer, healthier, more financially secure lives The challenge is an initiative of Manulife's Longevity Institute, driving solutions for a longer‑living Canadian society TORONTO, Oct. 21, 2026 /PRNewswire/ -- Manulife, in collaboration with UpLink, the World Economic Forum's early-stage innovation initiative, today...
ESTEVE CDMO expands its presence in Asia with a major investment and new manufacturing site in China
After more than two decades in China, ESTEVE CDMO marks a new chapter in its commitment to the country and the region. With more than $80 million invested, the new facility brings a new generation of manufacturing capabilities, with 250 m³ of reaction volume and potential capacity of more than 400+...
HelpMeSee Guwahati Training Operation Reaches 51 Ophthalmologists Across Northeast India
Successful collaboration with HMS Vision Private Limited and Sri Sankaradeva Nethralaya expands access to simulation-based cataract surgical training across four Northeast states GUWAHATI, India, Oct. 21, 2026 /PRNewswire/ -- HelpMeSee and HMS Vision Private Limited, in collaboration with Sri Sankaradeva Nethralaya (SSDN), announced the successful completion of a four-and-a-half-month simulation-based cataract...
CSL appoints Deborah Waterhouse as CEO & Managing Director
MELBOURNE, Australia, Oct. 21, 2026 /PRNewswire/ -- The Board of Directors of CSL Limited (ASX:CSL; USOTC:CSLLY) today announces that it has appointed Deborah Waterhouse as Chief Executive Officer and Managing Director of CSL from 1 February 2027. The appointment was made following an extensive global search process conducted by CSL's Board of Directors. Ms Waterhouse is a proven...
Getinge Interim Report July-September 2026: Increased profitability, strong cash flow and higher customer satisfaction
GOTHENBURG, Sweden, Oct. 21, 2026 /PRNewswire/ -- "We delivered organic growth both in order intake and in sales during the quarter, at the same time we increased profitability and generated strong cash flow." says Mattias Perjos, President & CEO of Getinge. Sales growth was primarily driven by Acute Care Therapies while Surgical Workflows contributed with a stable order intake,...
Samsung Biologics Reports Third Quarter 2026 Financial Results
Recorded Q3'26 revenue of KRW 1,490 billion and operating profit of KRW 640 billion Plant 5 ramp-up and U.S. manufacturing operations contribute to earnings performance Raised 2026 revenue growth guidance to 20% while advancing strategic investments in portfolio and capacity expansion INCHEON, South Korea, Oct. 21, 2026 /PRNewswire/ --...
